查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586056

癌症支持治療藥物市場：按治療層級、應用分類 - 全球預測 2025-2030

Cancer Supportive Care Drugs Market by Therapeutic Class (Antiemetics, Bisphosphonates, Erythropoiesis Stimulating Agents), Application (Breast Cancer, Colorectal Cancer, Liver Cancer) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年癌症支持治療藥物市場價值為206.2億美元，預計2024年將達214.6億美元，複合年成長率為4.50%，2030年將達280.6億美元。

支持性癌症治療藥物在癌症治療中至關重要，可以減輕治療相關的副作用並改善接受癌症治療的患者的生活品質。該市場包括多種藥物，包括止吐藥、造血生長因子、雙磷酸鹽和鎮痛藥，旨在控制癌症治療中常見的噁心、貧血和骨痛等症狀。全球癌症發生率的增加以及化療和放射線治療的進步強調了對這些支持性藥物的需求。這些藥物的應用涵蓋各個腫瘤科，主要用於醫院、癌症中心和門診設施，以支持成人和兒科病例。

主要市場統計
基準年[2023] 206.2億美元
預測年份 [2024] 214.6億美元
預測年份 [2030] 280.6億美元
複合年成長率（%） 4.50%

關鍵的成長要素包括對腫瘤學研究的投資增加、對個人化醫療的需求增加以及專注於提高患者照護標準。此外，該市場還見證了創新帶來的潛在商機，例如有針對性的支持性護理解決方案和數位健康工具的整合，以更有效地管理症狀和藥物依從性。快速的技術進步以及製藥公司和醫療保健提供者之間的合作方法為利用不斷變化的癌症治療需求提供了策略機會。然而，治療成本高、監管障礙和療效參差不齊等限制因素為市場擴張帶來了挑戰。此外，競爭格局需要不斷創新，以滿足新的病患需求和監管標準。

需要創新和研究的領域包括開發新型藥物輸送機制、探索生物相似藥以降低成本以及研究補充和替代療法。市場的動態性質高度依賴新的科學證據和技術，強調需要全面的市場策略以及與醫療保健系統的合作。總體而言，解決可近性和成本效益問題，同時注重提高療效和安全性，對於旨在癌症支持護理領域長期成長和影響的相關人員至關重要。

市場動態：揭示快速發展的癌症支持治療藥物市場的關鍵市場洞察

供需的動態交互作用正在改變支持性癌症藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 隨著人口老化的加劇，癌症盛行率不斷上升
    • 新產品核准和發布增加
    • 增加癌症支持治療藥物開發的研發活動
  • 市場限制因素
    • 癌症支持治療藥物高成本
  • 市場機會
    • 開發癌症治療新標靶治療藥物
    • 生物相似藥的採用增加，政府在醫療保健方面的支出增加
  • 市場挑戰
    • 與藥物攝取相關的副作用

波特五力：駕馭癌症支持治療藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解癌症支持治療藥物市場的外部影響

外部宏觀環境因素在塑造癌症支持治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解癌症支持治療藥物市場的競爭狀況

癌症支持治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣癌症支持治療藥物市場供應商的績效評估

FPNV 定位矩陣是評估癌症支持治療藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃癌症支持治療藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對癌症支持治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症發生率上升和老年人口增加
      • 新產品核准和發布增加
      • 增加癌症支持治療藥物的研發活動
    • 抑制因素
      • 癌症支持治療藥物成本高昂
    • 機會
      • 開發新的癌症治療標靶治療
      • 生物相似藥的採用增加以及政府在醫療保健方面的支出增加
    • 任務
      • 與藥物攝取相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按治療層級的癌症支持治療藥物市場

  • 止吐藥
  • 雙磷酸鹽
  • 促紅細胞生成素
  • 顆粒細胞增生因子
  • 非類固醇消炎劑
  • 鴉片類藥物

第7章癌症支持治療藥物市場：依應用分類

  • 乳癌
  • 大腸直腸癌
  • 肝癌
  • 肺癌
  • 攝護腺癌
  • 胃癌

第8章：美洲癌症支持治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太癌症支持治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲癌症支持治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Acacia Pharma Group PLC
  • Amgen Inc.
  • Aphios Corporation
  • AstraZeneca PLC
  • Bayer AG
  • Celldex Therapeutics
  • GSK PLC
  • Helsinn Healthcare SA
  • Heron Pharma
  • Ipsen Pharma
  • Johnson & Johnson
  • Merck & Co.
  • Novartis International AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-450A0628C601

The Cancer Supportive Care Drugs Market was valued at USD 20.62 billion in 2023, expected to reach USD 21.46 billion in 2024, and is projected to grow at a CAGR of 4.50%, to USD 28.06 billion by 2030.

Cancer supportive care drugs are crucial in oncology, providing relief from treatment-related side effects and enhancing patients' quality of life during cancer therapies. This market encompasses a wide range of medications, including antiemetics, hematopoietic growth factors, bisphosphonates, and analgesics, aimed at managing symptoms like nausea, anemia, and bone pain commonly associated with cancer treatments. The growing prevalence of cancer worldwide and advancements in chemotherapy and radiation therapies underscore the necessity for these supportive drugs. The application of these drugs spans across various oncology departments and is primarily utilized by hospitals, cancer centers, and outpatient facilities, where they support not only adult patients but pediatric cases as well.

KEY MARKET STATISTICS
Base Year [2023] USD 20.62 billion
Estimated Year [2024] USD 21.46 billion
Forecast Year [2030] USD 28.06 billion
CAGR (%) 4.50%

Key growth influencers include the increasing investment in oncology research, the rising demand for personalized medicine, and the focus on improving patient care standards. Additionally, the market is witnessing potential opportunities driven by innovations such as targeted supportive care solutions and the integration of digital health tools to manage symptoms and medication adherence more effectively. Rapid technological advancements and a collaborative approach between pharmaceutical companies and healthcare providers offer strategic opportunities to capitalize on the evolving needs of cancer care. Meanwhile, limitations such as high treatment costs, regulatory hurdles, and the variable efficacy of supportive drugs pose challenges to market expansion. Moreover, the competitive landscape can be stringent, requiring constant innovation to meet emerging patient needs and regulatory standards.

Areas ripe for innovation and research include the development of novel drug delivery mechanisms, exploration of biosimilars to reduce costs, and investigation into complementary and alternative therapies. The nature of the market is dynamic and heavily reliant on emerging scientific evidence and technology, emphasizing the need for comprehensive market strategies and collaboration with healthcare systems. Overall, maintaining a focus on enhancing efficacy and safety, while addressing accessibility and cost-effectiveness, will be crucial for stakeholders aiming to achieve long-term growth and impact in the cancer supportive care sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Supportive Care Drugs Market

The Cancer Supportive Care Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cancer coupled with increase in the geriatric population
    • Increasing approval and launch of new products
    • Increase in R&D activities for development of cancer supportive care drugs
  • Market Restraints
    • High cost of cancer supportive care drugs
  • Market Opportunities
    • Development of novel targeted therapies for the treatment of cancer
    • Rising adoption of biosimilar and increasing government expenditure on healthcare
  • Market Challenges
    • Side effects associated with consumption of drugs

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Supportive Care Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Supportive Care Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Supportive Care Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Supportive Care Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Supportive Care Drugs Market

A detailed market share analysis in the Cancer Supportive Care Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Supportive Care Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Supportive Care Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Supportive Care Drugs Market

A strategic analysis of the Cancer Supportive Care Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Supportive Care Drugs Market, highlighting leading vendors and their innovative profiles. These include Acacia Pharma Group PLC, Amgen Inc., Aphios Corporation, AstraZeneca PLC, Bayer AG, Celldex Therapeutics, GSK PLC, Helsinn Healthcare SA, Heron Pharma, Ipsen Pharma, Johnson & Johnson, Merck & Co., Novartis International AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Supportive Care Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Class, market is studied across Antiemetics, Bisphosphonates, Erythropoiesis Stimulating Agents, Granulocyte-Colony Stimulating Factors, Non-Steroidal Anti-Inflammatory Drugs, and Opioids.
  • Based on Application, market is studied across Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, and Stomach Cancer.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer coupled with increase in the geriatric population
      • 5.1.1.2. Increasing approval and launch of new products
      • 5.1.1.3. Increase in R&D activities for development of cancer supportive care drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of cancer supportive care drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of novel targeted therapies for the treatment of cancer
      • 5.1.3.2. Rising adoption of biosimilar and increasing government expenditure on healthcare
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with consumption of drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Supportive Care Drugs Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. Antiemetics
  • 6.3. Bisphosphonates
  • 6.4. Erythropoiesis Stimulating Agents
  • 6.5. Granulocyte-Colony Stimulating Factors
  • 6.6. Non-Steroidal Anti-Inflammatory Drugs
  • 6.7. Opioids

7. Cancer Supportive Care Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Colorectal Cancer
  • 7.4. Liver Cancer
  • 7.5. Lung Cancer
  • 7.6. Prostate Cancer
  • 7.7. Stomach Cancer

8. Americas Cancer Supportive Care Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cancer Supportive Care Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cancer Supportive Care Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Acacia Pharma Group PLC
  • 2. Amgen Inc.
  • 3. Aphios Corporation
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Celldex Therapeutics
  • 7. GSK PLC
  • 8. Helsinn Healthcare SA
  • 9. Heron Pharma
  • 10. Ipsen Pharma
  • 11. Johnson & Johnson
  • 12. Merck & Co.
  • 13. Novartis International AG
  • 14. Sanofi SA
  • 15. Sun Pharmaceutical Industries Ltd.
  • 16. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CANCER SUPPORTIVE CARE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CANCER SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER SUPPORTIVE CARE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER SUPPORTIVE CARE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. INDONESIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. INDONESIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MALAYSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. MALAYSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. PHILIPPINES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. PHILIPPINES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. SINGAPORE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. SINGAPORE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. TAIWAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. TAIWAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. THAILAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. THAILAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. VIETNAM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. VIETNAM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. DENMARK CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. DENMARK CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. EGYPT CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. EGYPT CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. FINLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. FINLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. ISRAEL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. ISRAEL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. NETHERLANDS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. NETHERLANDS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. NIGERIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. NIGERIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. NORWAY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. NORWAY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. POLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. POLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. QATAR CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. QATAR CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. RUSSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. RUSSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. SWEDEN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. SWEDEN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SWITZERLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. SWITZERLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. TURKEY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. TURKEY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED ARAB EMIRATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED ARAB EMIRATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 108. CANCER SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023